CRISPR Therapeutics AG
DE ˙ DB
€44.00 ↓ -6.00 (-12.00%)
2026-06-05
주가
SecurityDE:1CG / CRISPR Therapeutics AG
InstitutionSlow Capital, Inc.
Latest Disclosed Ownership91,223 shares
Latest Disclosed Value $ 4,339,479
Slow Capital, Inc. reports 19.04% increase in ownership of 1CG / CRISPR Therapeutics AG

On April 24, 2026 - Slow Capital, Inc. filed a 13F-HR form disclosing ownership of 91,223 shares of CRISPR Therapeutics AG (DE:1CG) valued at $3,557,697 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 26, 2026 disclosing 76,630 shares of CRISPR Therapeutics AG. This represents a change in shares of 19.04% during the quarter. The current value of the position is $4,013,812 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-24 2026-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 91,223 14,593 19.04 4,339 7.99 0.5636
2026-01-26 2025-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 76,630 3,343 4.56 4,018 -15.39 0.4799
2025-10-29 2025-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 73,287 -2,109 -2.80 4,750 29.51 0.5581
2025-07-23 2025-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 75,396 10,152 15.56 3,667 65.18 0.4491
2025-05-02 2025-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 65,244 3,669 5.96 2,220 -8.38 0.2973
2025-01-22 2024-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 61,575 -24,335 -28.33 2,424 -39.97 0.3431
2024-10-18 2024-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 85,910 6,694 8.45 4,036 -5.66 0.6183
2024-07-24 2024-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 79,216 11,647 17.24 4,278 -7.10 0.6926
2024-04-17 2024-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 67,569 933 1.40 4,606 10.41 0.7380
2024-01-31 2023-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 66,636 408 0.62 4,171 38.76 0.7258
2023-10-19 2023-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 66,228 2,405 3.77 3,006 -16.10 0.5519
2023-08-09 2023-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 63,823 -2,879 -4.32 3,583 18.80 0.6218
2023-04-26 2023-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 66,702 2,225 3.45 3,017 15.11 0.5643
2023-02-13 2022-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 64,477 20,295 45.93 2,621 -9.25 0.5833
2022-10-27 2022-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 44,182 -1,036 -2.29 2,887 5.06 0.6239
2022-07-28 2022-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 45,218 2,886 6.82 2,748 3.42 0.6672
2022-05-02 2022-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 42,332 12,035 39.72 2,657 15.72 0.4963
2022-02-08 2021-12-31 13F CRISPR Therapeutics NAMEN AKT H17182108 30,297 11,629 62.29 2,296 9.86 0.3924
2021-10-21 2021-09-30 13F CRISPR Therapeutics NAMEN AKT H17182108 18,668 54 0.29 2,090 -30.63 0.3831
2021-07-29 2021-06-30 13F CRISPR Therapeutics NAMEN AKT H17182108 18,614 2,227 13.59 3,013 27.18 0.5697
2021-05-20 2021-03-31 13F/A-1 CRISPR Therapeutics NAMEN AKT H17182108 16,387 87 0.53 2,369 -5.05 0.5141
2021-05-05 2021-03-31 13F CRISPR Therapeutics NAMEN AKT H17182108 12,481 -3,819 1,521 0.3703
2021-02-11 2020-12-31 13F CRISPR Therapeutics NAMEN AKT H17182108 16,300 280 1.75 2,495 86.33 0.5965
2020-11-04 2020-09-30 13F CRISPR Therapeutics NAMEN AKT H17182108 16,020 2,977 22.82 1,339 39.62 0.3648
2020-08-10 2020-06-30 13F Crispr Therapeutics Agnamen Akt NAMEN AKT H17182108 13,043 130 1.01 959 75.00 0.2815
2020-05-12 2020-03-31 13F Crispr Therapeutics Agnamen Akt NAMEN AKT H17182108 12,913 -3,611 -21.85 548 -45.58 0.2069
2020-02-14 2019-12-31 13F Crispr Therapeutics Agnamen Akt NAMEN AKT H17182108 16,524 3,462 26.50 1,007 88.22 0.3114
2019-11-06 2019-09-30 13F Crispr Therapeutics Agnamen Akt NAMEN AKT H17182108 13,062 -175 -1.32 535 -14.13 0.1892
2019-08-01 2019-06-30 13F Crispr Therapeutics Agnamen Akt NAMEN AKT H17182108 13,237 -248 -1.84 623 29.25 0.2570
2019-05-16 2019-03-31 13F Crispr Therapeutics Agnamen Akt NAMEN AKT H17182108 13,485 13,485 482 0.1917
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.